Objective: Conventional clinical wisdom has often been nihilistic regarding the prevention and management of acute kidney injury (AKI), despite its being a frequent and morbid complication associated with both increased mortality and cost. Recent developments have shown that AKI is not inevitable and that changes in management of patients can reduce both the incidence and morbidity of perioperative AKI. The purpose of this narrative review was to review the epidemiology and outcomes of AKI in patients undergoing vascular surgery using current consensus definitions, to discuss some of the novel emerging risk stratification and prevention techniques relevant to the vascular surgery patient, and to describe a standardized perioperative pathway for the prevention of AKI after vascular surgery.
Until recently, conventional clinical wisdom has been largely nihilistic regarding the prevention and management of acute kidney injury (AKI). 1 In part, this perspective may have been influenced by the frequency with which this complication occurs in association with other postoperative morbidity events, leading some providers to question whether AKI is simply a bystander to the complex physiologic perturbations of the postoperative patient. However, recent developments have shown that AKI is not inevitable and that relatively small changes in management of patients can reduce both the incidence and morbidity of perioperative AKI. [2] [3] [4] Moreover, the emerging implications of cardiachepatic-renal organ crosstalk have increasingly placed the kidney into a more central role as a physiologic regulator of organ dysfunction. 5 From the Department of Surgery, Malcom Randall VAMC a Kidney disease and vascular disease are closely linked. Patients with chronic kidney disease (CKD) have been shown to have accelerated atherosclerosis and higher vascular calcification burdens 6, 7 as well as an increased incidence of cardiovascular events and death. 8 The two conditions also share several common risk factors, such as hypertension, diabetes, and hyperlipidemia, that contribute to a high concurrent prevalence. Given this relationship, patients undergoing vascular surgical procedures are likely to have higher rates of preexisting kidney disease and to be at higher risk for development of postoperative complications such as AKI. The implications of this elevated kidney disease burden are highlighted by the dramatically increased risk in shortand long-term mortality for vascular surgery patients experiencing postoperative AKI (pAKI). We review the epidemiology and outcomes of AKI in patients undergoing vascular surgery as well as some of the novel emerging risk stratification and prevention techniques relevant to the vascular surgery patient.
METHODS
We performed a critical review of the literature on AKI in the vascular surgery patient using the PubMed and MEDLINE databases and Google Scholar through September 2017 using web-based search engines. We used the search engine tools for relevant or related articles along with a search of the bibliographies of relevant articles and manuscripts citing these articles to find additional relevant publications. The search terms used included acute kidney injury, AKI, surgery, vascular surgery, cardiovascular surgery, epidemiology, outcomes, prevention, therapy, and treatment. We also searched the guidelines and publications available online from the organizations Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Network, and Acute Dialysis Quality Initiative. We emphasized articles published within the past 5 years, but older manuscripts were included for historical context or if they were still clinically relevant. As our interest is in describing the current state of the art in a rapidly evolving field rather than in evaluating randomized trials of a specific intervention, we did not limit ourselves to the protocols of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Definitions and epidemiology. AKI is one of the most common yet underdiagnosed postoperative complications after any type of surgery. Historically, there was wide variability in the reported incidence of pAKI because of the widely variable definitions of AKI that were in use. 9, 10 Previous definitions focused on large increases in serum creatinine concentration or the need for renal replacement therapy, which led to AKI being portrayed as a rare and fatal complication. (Table I) . 11, 15, 16 The VQI is a collaborative of regional quality groups collecting and analyzing perioperative and 1-year follow-up data in an effort to improve patient care. 14 The VQI is governed by the Society for Vascular Surgery Patient Safety Organization, which provides oversight of data sharing, outcome and quality measure analyses, and dissemination of information. Data collection for the VQI database is procedure dependent. Data collected to assess renal dysfunction vary from none (for amputations, cava filter placements, hemodialysis access procedures, and carotid procedures) to measurement of highest postoperative serum creatinine concentration and recording of any dialysis (endovascular aortic procedures) to a staged measurement of any change in renal function (for open aortic procedures and peripheral bypass procedures). Although it does not use the same staging as the consensus KDIGO guidelines, the VQI database does recognize the importance of even mild degrees of AKI, with any increase in serum creatinine concentration of >0.5 mg/dL recorded as a stage 1 change of renal function.
The reported epidemiology and outcomes associated with pAKI have been evolving since the publication of these new consensus definitions. The incidence of AKI after major vascular surgery using the current criteria has been reported as high as 49% across a cohort of all vascular surgery patients, although there are significant differences, depending on the type of procedure performed. 17 Peripheral vascular procedures have some of the lowest rates, from 4% for patients undergoing infrainguinal lower extremity bypass up to 19% for endovascular revascularization of critical limb ischemia [18] [19] [20] [21] (Fig 1) .
Thoracic and abdominal aortic procedures generally have higher rates of pAKI than peripheral vascular operations. Elective endovascular aneurysm repair of infrarenal abdominal aortic aneurysms (AAAs) has reported incidences of pAKI between 5.5% and 18%. 22, 23 One recent study reported a rate as low as 2.9%; however, the investigators defined AKI as an increase in serum creatinine concentration of 0.5 mg/dL or a new dialysis requirement, differing from the more sensitive KDIGO consensus criteria. 24 More complex AAA repairs have higher rates of AKI, up to 28% for those requiring branched or fenestrated devices and as high as 32% for juxtarenal AAAs employing a snorkel or chimney approach. 25, 26 Similarly, the recently reported incidence of AKI after thoracic endovascular aortic repair for thoracic aortic aneurysms was 9.7% 27 and 30% after repair of Stanford type B acute aortic dissections. 28 Open aortic procedures have significantly higher incidences of pAKI compared with endovascular approaches. Patients undergoing elective open aortic repairs of infrarenal AAAs have pAKI rates of up to 26%. 22 This risk increased for more proximal aneurysms, up to 47% for juxtarenal and 68% for suprarenal aneurysms. 29 Emergent repair of a ruptured aneurysm has the highest risk, with some series documenting rates of 75%. 30, 31 Open thoracic repairs had similarly elevated incidence of renal complications compared with their endovascular counterparts, for which pAKI rates can be 34% for elective thoracic aortic aneurysms, 45% for Stanford type A dissections, and 48% for aortic arch procedures. 27, 32, 33 Outcomes. Repeatedly, pAKI has been shown to be associated with increases in risk for other complications, short-and long-term mortality, hospital cost, and resource utilization among all surgical patients. Patients who develop AKI after major vascular surgery have higher rates of other postoperative complications, such as infection, coagulopathy, anemia, need for mechanical ventilation, rates of tracheostomy, and cardiovascular events. 17, 19, 20, 22, 23, 34, 35 Long term, pAKI patients are more likely to have subsequent episodes of AKI, to develop CKD, to have cardiovascular disease, and to have worse survival. 17, 19, [36] [37] [38] Both in-hospital mortality and long-term mortality are significantly elevated among vascular patients who develop pAKI compared with those who do not. 18, 19, 34 Not only does this reduced survival risk persist for up to 10 years after the original episode, but it has been shown to exist even among patients who achieve full recovery Notably, cardiovascular-specific mortality is particularly elevated in this population of patients. 41 In a cohort of all vascular surgery patients, for patients with normal preoperative renal function who developed AKI after surgery, 5-year cardiovascular-specific mortality was 22% compared with 10% for patients without AKI. 42 Even the least severe stage 1 AKI confers additional mortality risk, which increases with worsening AKI severity. 34, 40, 43 Outcomes in the important prospective vascular surgery clinical trials, for both peripheral arterial disease and aortic disease, either do not mention AKI 44 or provide minimal outcomes information, such as a new need for dialysis 45 or a proscribed drop in estimated glomerular filtration rate.
46-51
The development of pAKI is associated with a substantial increase in hospital cost and resource utilization. These patients have longer intensive care unit (ICU) and overall hospital lengths of stay as well as a higher likelihood of being discharged to a skilled nursing facility or rehabilitation center. 34, 38, 43 A large retrospective study of major surgery patients demonstrated a mean adjusted hospital cost of $42,600 for patients who developed pAKI compared with $26,700 for those who did not, a 59% increase. 34 This cost differential increased incrementally with worsening RIFLE AKI stage. A similar study of vascular surgery patients identified that either pre-existing CKD or pAKI results in additional adjusted incremental costs of $8900 and $9100, respectively, whereas the simultaneous presence of both of these conditions contributed to a $19,100 adjusted incremental cost increase. 17 The additional costs that these patients incur draws from across several different categories of care, including the ICU, medical supplies, laboratory, pharmacy, and respiratory services. 43 Recent studies have shown that negative outcomes after AKI are not set in stone and in fact are modifiable with proactive prevention and management actions taken by the surgeon. Two recent prospective randomized trials of biomarker-guided prediction and management of pAKI in surgical patients, using the urinary biomarker TIMP-2 d IGFBP7 to stratify patients into either a KDIGO care bundle or standard care, have shown that aggressive monitoring and management of pAKI in patients undergoing major surgery can lead to better outcomes. 3, 4 In both studies, the overall incidence of pAKI and the incidence of more severe stages of pAKI were reduced in the study patients. Risk stratification and prediction. An individual patient's risk for development of pAKI is determined by a complex interaction of preoperative kidney health, physiologic reserve affecting the patient's capacity to withstand surgical stress, and type and course of the surgical procedure the patient undergoes. Moreover, this risk is unlikely to be a static value but instead is actually a dynamic variable that changes in response to intraoperative and postoperative events that are difficult to predict in the preoperative setting. Whereas attempts to stratify and to predict AKI risk preoperatively are of primary importance, the ability to analyze and to interpret the wealth of intraoperative clinical data and to adjust risk for the events that can dramatically modify the risk, such as intraoperative hypotension or use of nephrotoxic drugs, will allow application of risk-targeted preventive strategies throughout the continuum of perioperative care.
There are many tools now available to evaluate preoperative risk for pAKI, including clinical data, plasma and urine biomarkers, and advanced imaging techniques. The large population of patients at low risk needs only basic stratification using clinical evaluation of known risks for AKI, such as CKD and albuminuria. 52 Patients at higher risk will need more complex and thus more expensive assessment of risk. Clinical risk scores were among the first strategies to predict patients who would develop AKI. Their utility is limited by their inability to incorporate dynamic intraoperative factors, and they often have been developed for a specific type of surgery and are not widely applicable. In a systematic review of several clinical risk scores for cardiac surgery patients, only moderate performance was observed with an area under the receiver operating characteristic curve (AUC) between 0.77 and 0.84. 53 Many of these scores relied on easily abstracted preoperative variables and simple logistic regression analysis. A model designed for risk prediction in patients undergoing vascular surgery performed relatively poorly with AUC of 0.67 when only preoperative variables were used and showed only a modest improvement to 0.72 when some intraoperative variables were incorporated. 54 More recently, advanced computational approaches using techniques such as machine learning models that use electronic health record data have shown better performance. One such model developed for AKI prediction for patients undergoing any major surgery reported an AUC of 0.86 on internal validation. 55 Models that are able to capture and to process large volumes of data in real time and to process them automatically to create risk profiles are likely to emerge as superior approaches to risk calculation compared with regression analyses. 56 Until such tools are developed and validated, risk scores for pAKI cannot be recommended for routine clinical use. Advanced imaging techniques are being developed and evaluated as a means to assess kidney function and AKI. The renal resistive index (RRI) uses Doppler ultrasound imaging to assess the resistance to blood flow in the kidney, and an elevated RRI has been associated with increased risk for AKI. 57 An elevated RRI has been associated with increased risk and severity of AKI in sepsis and in patients who underwent cardiac and orthopedic surgery. [58] [59] [60] [61] [62] It has also shown potential to predict the progression of pAKI. 63 Contrast-enhanced ultrasound to assess renal perfusion has demonstrated promise as a predictor of risk and prognosis of surgical patients who develop AKI. [64] [65] [66] Finally, blood oxygenation level-dependent magnetic resonance imaging uses deoxyhemoglobin as a contrast agent to study intrarenal oxygenation, and although it is promising in animal studies of AKI, it has not yet found a place in clinical practice. [67] [68] [69] Whereas none of these imaging techniques are in common clinical practice, and when they are used, it is typically under the guidance of a nephrologist, they are evolving rapidly and likely will be seen more often. Urine and plasma biomarkers for AKI are a significant focus of research efforts. Currently, serum creatinine concentration is the most widespread test used for diagnosis and monitoring of AKI. Unfortunately, serum creatinine concentration is a measurement of renal function rather than of renal injury, and degradation of function is not observed until tubular damage is already well under way. A suitable biomarker would detect tubular stress before the structural damage that results in functional impairment and would have specificity for AKI as opposed to CKD or other disease processes. 70 Two markers that showed some initial potential but have been hampered by the previously described difficulties are neutrophil gelatinase-associated lipocalin and cystatin C. [71] [72] [73] [74] [75] More recently, the combination of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) has performed well in the prediction of moderate to severe AKI in critically ill patients in several multicenter studies and has been approved by the Food and Drug Administration. [76] [77] [78] These markers are cell cycle arrest proteins released by renal tubular cells in response to stress from toxins, inflammation, and hypoxia and may indicate the risk of renal injury before any permanent tubular damage. Validation of these markers demonstrated sensitivity of 89% and negative predictive value of 97% for predicting AKI in critically ill patients within 12 hours.
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The TIMP-2 d IGFBP7 test has been the most accurate biomarker developed to date, is Food and Drug Administration approved and commercially available, and has been shown to have clinical utility in surgery patients.
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Prevention and treatment. Optimal perioperative care of the vascular patient, using strategies evaluated in vascular surgery and in other major surgery, may prevent pAKI or limit the extent of injury if pAKI occurs (Table II) . A protocol that emphasizes optimal hemodynamic function along with avoidance of warm renal ischemia time and renal toxins (especially intravenous radiographic contrast agents) has been shown to be effective in preventing AKI in the vascular patient. 22 However, many other approaches have been explored. Given that most patients undergoing vascular surgery will have numerous cardiovascular comorbidities, there has been significant interest in the pharmacologic optimization of renal function, particularly in the preoperative setting. In general, these interventions have been of little or no use in preventing pAKI. Antihypertensive therapies, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), have been proven beneficial for primary prevention and management of CKD; however, their use in the immediate perioperative setting is associated with postoperative hypotension. [81] [82] [83] Several recent studies have demonstrated that preoperative use of ACE inhibitors or ARBs is associated with higher rates of pAKI after noncardiac surgery. [84] [85] [86] Similarly, in a large prospective cohort of cardiac surgery patients, ACE inhibitor and ARB use was associated with higher rates of functional pAKI by serum creatinine values; however, no evidence of structural kidney injury was observed by measurement of urinary biomarkers of structural damage, such as neutrophil gelatinaseassociated lipocalin, kidney injury molecule 1, interleukin 18, and liver fatty acid-binding protein. 87 Whereas no prospective trials have yet been done, given these findings, clinicians should consider holding ACE inhibitors and ARBs in the 24 hours immediately before surgery if possible. Other drugs that have been evaluated for their potential to prevent pAKI include N-acetylcysteine, sodium bicarbonate, dopamine, fenoldopam (a selective D1 receptor partial agonist), theophylline, atrial natriuretic peptide, clonidine, and aspirin, and none have been shown to be clinically effective. 88, 89 Despite being commonly used during procedures requiring suprarenal aortic cross-clamping, mannitol has not been shown to significantly decrease rates of pAKI and may actually increase the risk among patients who receive intravenous administration of contrast material. 90, 91 Initial trials of remote ischemic preconditioning as a technique to prevent pAKI were disappointing; however, recent trials have demonstrated benefits in both cardiac and vascular patients. [92] [93] [94] [95] Remote ischemic preconditioning, which uses the concept of repeated cycles of transient ischemia in an extremity to enhance ischemia tolerance in visceral organs, has been shown to protect against many forms of AKI, including contrast-induced AKI when used before elective coronary angiography, and has been associated with decreased lengths of hospital and ICU stay in patients undergoing vascular surgery. 93, 96 In vascular surgery, the technique can include intermittent clamping of the common iliac artery after access to the peritoneal cavity or intermittent activation of a tourniquet on the thigh or arm. 97 The mechanisms of remote ischemic preconditioning are poorly understood, but they are believed to include modification of mitochondrial function, metabolic downregulation, and temporary cell cycle arrest. In addition, a recent study demonstrated elevated plasma vascular endothelial growth factor levels in an animal model of remote ischemic preconditioning. 98 Although it is not in widespread practice, particularly in vascular surgery, studies continue to show improved outcomes in patients in whom the technique is used. 92, 99 Perioperative techniques that have been shown to minimize pAKI in cardiac and vascular surgery include cell salvage techniques, avoidance of anemia, avoidance of hypotension, enhancement of oxygen delivery, and minimization of allogeneic blood product transfusion. [100] [101] [102] [103] [104] The use of volatile anesthetics has been shown to provide renal protection in patients undergoing cardiovascular surgery. 105 An early meta-analysis of goal-directed fluid management showed reduced complication rates in cardiac patients but no significant benefits in vascular patients, although rates of AKI were reduced. 106 Use of bedside ultrasound in the ICU to assess renal perfusion and RRI has demonstrated some promising results as an adjunct to resuscitation. 107 However, further studies are warranted, given the difficulty in determining optimal end points for both resuscitation and targeted mean arterial pressure goals in the prevention of AKI. Technical considerations relating to the duration and placement of vascular clamps may also have an impact on the development and progression of renal ischemia. Extensive dissection with associated embolization of atheromatous material may precede the development of renal ischemia. 108 Renal artery stenosis, if detected preoperatively, may be treated with angioplasty, with stent, or concurrently at the time of surgery. Several studies have demonstrated the feasibility of unilateral or bilateral renal artery endarterectomy, with short-term improvements in renal function and no significant difference on mortality. [109] [110] [111] [112] [113] [114] Duration of aortic cross-clamp time with renal ischemia >23 minutes was associated with renal dysfunction after juxtarenal AAA repair. 113 Hypothermic perfusion and maintenance of renal perfusion have been described in small cohorts of patients undergoing aortic surgery, with no long-term elevations in serum creatinine concentration on hospital discharge. 115 Timely referral to and ongoing involvement with the nephrology service have been shown to minimize sequelae related to AKI. 116 Delays in nephrology consultation are associated with increased mortality and dialysis dependence rates at hospital discharge, whereas early nephrology consultation has been shown to reduce the risk of worsening kidney function in diverse populations of patients. [116] [117] [118] Immediate nephrology consultation after AKI can influence outcomes both by ensuring that care follows current AKI guidelines and through appropriate initiation of renal replacement therapy when indicated. 119 When and how to initiate renal replacement therapy and who makes that decision for the patient with AKI are controversial. Later follow-up by a nephrologist, once a patient has been discharged from the hospital, has also been shown to have an impact on all-cause mortality in survivors of severe kidney injury and to reduce subsequent deterioration of renal function.
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The 2012 KDIGO AKI guidelines and recommendations from a recent Acute Dialysis Quality Initiative consensus report on renal recovery after AKI both suggest that close follow-up after AKI can improve outcomes. 122, 123 This follow-up care should be multidisciplinary and coordinated between a patient's primary care practitioners, surgical providers, and nephrology consultants.
A standardized perioperative pathway for prevention of AKI after vascular surgery. Routine assessment of the risk for AKI in the perioperative period is an essential part of high-quality care for the vascular surgery patient. An optimal and cost-effective strategy, combining both risk stratification and prevention, matches the complexity of interventions to the risk profile of the individual patient. Clinical risk stratification is applied to all patients to identify the smaller population of patients with high clinical risk who warrant further assessment with biologic and imaging markers. Preventive interventions are used throughout the continuum of perioperative care, with the timing and target population of patients determined by the risk profile and expected benefit from each intervention. Considering the high prevalence of AKI, the high morbidity burden it imposes on other organ systems, and the associated long-term adverse outcomes, all phases of prevention should be included. Primary prevention of new episodes of AKI, secondary prevention after AKI (the mitigation of further injury as well as facilitation of renal recovery), and tertiary prevention (the treatment of complications of AKI that affect distant organs) are all essential components of the perioperative care of the vascular surgery patient.
Standardized clinical assessment and management pathways (SCAMPs) are used to standardize care in the perioperative period. They synthesize current medical knowledge with best clinical judgment and local practice experience to decrease practice variability and to improve patient care. 124 Using KDIGO clinical guidelines as a framework and our institutional perioperative registry outcome data, 38, 39, 125 we have developed a perioperative AKI SCAMP for vascular surgery patients: a multilayered approach combining risk assessment with a set of preventive strategies to prevent AKI and to decrease its complications among vascular surgical patients (Fig 2) . This process incorporates the routine preoperative and immediate postoperative assessment of the patient's susceptibility to new injury, the degree of any renal insult, and the resulting distress or damage sustained by that insult. Based on the results of this analysis, interventions for primary and secondary prevention of AKI are initiated, followed by frequent reassessment of kidney stress for 48 hours after surgery. Development of such a clinical pathway requires the surgeons, intensivists, and specialty consultants to define the pathway for a specific institution. For all vascular surgical patients, we use a stepwise approach starting with clinical risk stratification to identify those patients who would benefit from more aggressive evaluation. Clinical risk stratification includes assessment of renal susceptibility to injury, general health factors, and those operative factors and clinical exposures that can cause renal injury. Renal susceptibility to injury incorporates estimated glomerular filtration rate and CKD stage if any, previous episodes of AKI, and determination of albuminuria. A formal determination of functional renal reserve with a kidney stress test 126 rarely is indicated for more precise risk stratification among patients without apparent CKD but with considerable risk due to age or other comorbidities, such as heart failure, hypertension, chronic obstructive pulmonary disease, diabetes, or liver disease. General health factors of importance include the overall comorbidity burden and assessment of frailty and nutritional status. [127] [128] [129] [130] This assessment is one part of our overall preoperative patient assessment and informs our decision-making on preoperative optimization and which procedure to offer the patient, if any. Operative factors include specific technical details and emergent or prolonged surgery. Perioperative exposures include any hypotension, hypoxia, blood transfusion, and any history of nephrotoxic medications or intravenous administration of contrast material. Once the patient is out of surgery, the preoperative assessment and the operative course determine further management. Those patients with no risk factors are managed with standard postoperative care. Patients with any positive risk factors are evaluated for kidney stress using the urinary biomarker TIMP-2 d IGFBP7, and care is then stratified according to the result. The TIMP-2 d IGFBP7 score is calculated as the product of the measured concentrations of the two biomarkers, TIMP-2 and IGFBP-7, and is recorded as a value between 0.04 and 10.0. 76, 79 A TIMP-2dIGFBP7 score of <0.3 indicates a patient at low risk for AKI who can be managed without specific AKI attention. A score of 0.3 to 2.0 indicates a patient at high risk for AKI and management according to our AKI bundle. A score of >2.0 indicates a patient at critical risk for AKI and management according to our AKI bundle. Our AKI bundle uses checklist implementation of simple preventive strategies, including monitoring and optimizing of hemodynamic status by goal-directed fluid management and blood pressure control, strict avoidance of nephrotoxic medications, strict avoidance of glucose variability, and careful monitoring of drug levels to adjust dosing in accordance with the glomerular filtration rate. The goal of this phase is to prevent the progression of tubular stress toward functional decline whenever possible and to avoid the negative consequences of fluid overload and drug toxicity in patients with established tubular stress and thus to prevent further decline in renal function. The bundle is repeated every 12 hours until resolution of the tubular stress or AKI. For patients at critical high risk of AKI (TIMP-2dIGFBP7 > 2.0), our AKI bundle incorporates all of these and adds a clinical action pathway directed by our nephrology consultation service focused on identification of the cause of AKI using specialized clinical, laboratory, and imaging tools and consideration for early renal replacement therapy. Early renal replacement therapy may be appropriate for patients with large levels of tubular stress and rapid functional decline, in whom impaired handling of fluids may endanger other organs. Our preliminary experience with SCAMP implementation and compliance has been excellent, and recent studies have confirmed our preliminary findings that risk stratification-guided implementation of prevention bundles translates into better renal outcomes after surgery. 3, 4 CONCLUSIONS AKI remains a prevalent postoperative complication among vascular surgery patients and has a significant impact on morbidity, mortality, and cost. With more widespread adoption of consensus criteria and as more accurate diagnostic modalities continue to emerge, it has become increasingly recognized as a major factor affecting patient outcomes. Despite increasing recognition, however, better strategies of prevention and management have been slower to develop. Continued vigilance in the preoperative assessment and perioperative management of these patients is needed to minimize the morbidity and mortality associated with pAKI. 
